AC Immune Positive Interim Results from Phase 2 Trial of Immunotherapy in Early Parkinson’s

 

• Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations
• 100% of patients receiving ACI-7104.056 responded against the target antigen
• ACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date

Based on further interim results to be reported in H1 2025 including pharmacodynamic data, AC Immune may decide to initiate Part 2 of VacSYn with up to 150 patients. Patients from Part 2 will also be evaluated for progression of motor and non-motor symptoms of the disease, as well as digital, imaging, and fluid biomarkers. The aim is to establish early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study.

https://www.globenewswire.com/news-release/2024/11/14/2981035/0/en/AC-Immune-Reports-Positive-Interim-Results-from-Phase-2-Trial-of-ACI-7104-056-Active-Immunotherapy-in-Early-Parkinson-s-Disease.html